Anthera pharma - What More After VISTA-16 Failure?
Discontinuation of VISTA-16 due to lack of efficacy is a big blow for Anthera Pharma (ANTH); though the PhII data of its key drug Varespladib (formerly A-002, PhIII, Acute Coronary Syndrome-ACS, unpartnered) vs. competitor GSK/HGSI’s Darapladib (lipoprotein-associated phospholipase A2 inhibitor, Lp-PLA2) was promising. ANTH announced positive interim data from its PhIIb trial – PEARL-SC of Blisibimod (formerly A-623, SC PhIIb, Lupus, a selective peptibody antagonist of BLyS/BAFF), showing statistically significant reduction of B-cells with its monthly and weekly SC dosing however, under the current competitive scenario, the advantages of Blisibimod vs. Benlysta are not very compelling dimming its chances of partnership or commercial potential.
COMPANIES MENTIONED
Anthera pharma
Anthera pharma
More Publications
ANTHERA PHARMA - Portfolio of More than Just a "Me Too" = Better Commercial Opportunity
US$ 90.00
June 2011
4 pages
Pharma Social Media Campaigns: Current Thinking and Future Outlook
US$ 395.00
February 2011
51 pages
Market Access Brazil: Unlocking Pharma Potential
US$ 795.00
July 2011
38 pages
Roche & Genentech: a Model for Future Biotech Deals?
US$ 295.00
August 2009
42 pages
